BridgeBio Pharma Inc (BBIO) — Cash Flow Reinvestment Rate
Latest as of June 2024:
0.07x
BridgeBio Pharma Inc (BBIO) has a Cash Flow Reinvestment Rate of 0.07x as of June 2024, reinvesting $5.49 Million (capex $2.45 Million plus investments $3.04 Million) from operating cash flow of $74.70 Million. Explore BridgeBio Pharma Inc operating cash flow efficiency to assess how effectively this company generates cash.
Reinvestment Rate
0.07x
(Capex + Investments) / Operating CF
Total Reinvested
$5.49 Million
Capex + Investments
Operating Cash Flow
$74.70 Million
USD
Capital Expenditures
$2.45 Million
USD
Annual Cash Flow Reinvestment Rate for BridgeBio Pharma Inc (None–None)
Year-by-year capital reinvestment analysis for BridgeBio Pharma Inc. For live market cap and broader valuation context, see BBIO market cap overview.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow